Introduction
Human papillomaviruses (HPVs) are small DNA tumorviruses which comprise a heterogenous group of more than 80 dierent genotypes (for review, see de Villiers, 1989) . There is substantial epidemiological and molecular biological evidence showing that certain types of HPV (HPV 16, 18, 33, 35 and others) are etiologically involved in the development of cervical cancer, the second leading cause of cancer in women worldwide (zur Hausen, 1996) . Despite of the physical and functional interactions of the viral oncogenes E6 and E7 with presumptive tumor suppressor proteins such as p53 (Werness et al., 1990) and the retinoblastoma gene product Rb (Dyson et al., 1989) , DNA-mediated gene transfer experiments into primary human keratinocytes (DuÈ rst et al., 1987; Kaur and McDougall, 1989) only resulted in immortalized cells, which were non-tumorigenic after heterotransplantation into immunocompromised animals (DuÈ rst et al., 1995) . Progression to cervical cancer is therefore considered as a multi-step process, where viral infection is necessary but not sucient for tumor induction (reviewed in zur Hausen and RoÈ sl, 1994) .
Beside the immunological aspects, there also exists experimental evidence for an intracellular surveillance mechanism negatively interfering with the expression of the viral oncogenes E6/E7 (RoÈ sl et al., 1988 (RoÈ sl et al., , 1991 Smits et al., 1990 Smits et al., , 1992 zur Hausen, 1986 . Monitoring viral transcription in low-grade cervical intraepithelial neoplasias by RNA/RNA in-situ-hybridization, only low abundance of E6/E7 gene expression has been observed within the basal cell layers, whereas virus-speci®c transcription was found to be uniformly elevated in undierentiated cells of specimens obtained from cancer patients (Crum et al., 1989; DuÈ rst et al., 1991) . For this reason, the working hypothesis has been put forward suggesting that the viral upstream regulatory region (URR) might be a direct target for an intracellular regulatory pathway, which negatively interferes with viral transcription at the level of E6/E7 mRNA initiation zur Hausen and RoÈ sl, 1994) . This cannot only be deduced from RNA/ RNA in-situ hybridization studies on primary tissue sections, but also from somatic cell hybridization experiments (Stanbridge, 1984) demonstrating a differential regulation of E6/E7 gene expression in tumorigenic and non-tumorigenic cells (RoÈ sl et al., 1988; Bosch et al., 1990 ; Bartsch et al., 1992; Khan et al., 1993) . Monitoring cytokine sensitivity for instance, TNF-a treatment results in a selective down-regulation of HPV 18 transcription exclusively in non-malignant HeLa-®broblast hybrids, while viral gene expression in tumorigenic segregants obtained from the very same hybrids or in parental HeLa cells was not aected under the same experimental conditions (RoÈ sl et al., 1994) .
In order to understand the processes controlling HPV transcription within cells of dierent genetic background in greater detail, we started to analyse the biochemical properties of the transcription factor AP-1, which is known to play a central role in the transcriptional regulation of almost all HPV types investigated so far (for review, see RoÈ sl and Schwarz, 1997) . AP-1 represents a dimeric protein, consisting either of homodimers between c-Jun, JunB and JunD or of heterodimers with members of the Fos-family (cFos, FosB, Fra-1 and Fra-2) by physically interacting via an intramolecular`leucine zipper' region (for review, see Angel and Karin, 1991) . Site-directed mutagenesis of the corresponding AP-1 binding sites within the viral control regions almost completely abolishes transcription of URR-driven reporter constructs either under transient transfection conditions (Oord and Beard, 1990; Butz and Hoppe-Seyler, 1993; Cripe et al., 1990; Thierry et al., 1992) or in stable dierentiation-dependent infection assays in organotypic`raft' cultures (Parker et al., 1997; Zhao et al., 1997) .
The reason for reconsidering the role of AP-1 in HPV-linked carcinogenesis was mainly due to previous experiments investigating the eects of antioxidative drugs such as pyrrolidine-dithiocarbamate (PDTC) on viral gene expression . Although PDTC increases the DNA binding anity of AP-1 to its cognate recognition site within the URR in immortalized human keratinocytes, HPV 16 gene expression becomes selectively suppressed at the level of initiation of transcription. Gel-retardation assays with antibodies raised against the dierent components of AP-1 revealed that the transcription complex, formerly consisting of c-Jun homodimers was altered. Despite a high synthesis rate of c-Fos, c-Jun became phosphorylated and primarily heterodimerized with Fra-1. Since elevated levels of Fra-1 abrogate transactivation of AP-1 prototype c-Jun/c-Fos-complexes on AP-1 responsive marker genes (Suzuki et al., 1991; Yoshioka et al., 1995) , it was reasonable to assume that viral suppression was mainly due to the reorganization of AP-1 transcription complexes in PDTC treated cells .
To address the question, whether modi®cations in AP-1 composition might be a general feature of a negative regulatory pathway controlling HPV transcription in phenotypically`normal' cells, non-tumorigenic HPV 18-positive HeLa-®broblasts hybrids, tumorigenic segregants of the same hybrids (Stanbridge, 1984) as well as unfused HeLa cells were used as a genetically de®ned in vitro model system to monitor altered expression of Jun/Fos family protein members on the basis of their dierential sensitivity against cytokines and growth properties in nude mice.
In the present study evidence is provided that AP-1 transcription complexes in non-tumorigenic hybrids harbor a 4 ± 5-fold higher amount of Fra-1 than their tumorigenic counterparts. Moreover, fra-1 becomes induced both on transcriptional and on protein level by TNF-a exclusively in non-malignant cells, which correlates with the down-regulation of HPV 18 gene expression. In contrast, while tumorigenic cells harbor substantial amounts of c-Fos, non-tumorigenic HeLa®broblast hybrids completely lack this`classical' dimerization partner of c-Jun. In order to test whether over-expression of c-Fos can compete out Fra-1 from AP-1 complexes and whether this aects cytokine sensitivity and the in vivo growth, non-tumorigenic HPV18-positive hybrids were stably transfected with a c-fos expression vector under the control of a SV40 promoter/enhancer element. Reconstitution of sufficient amounts of c-Fos in`444'-hybrids results in tumorigenic cells, where the ratio between Jun and Fra-1 was changed in favor of Jun/c-Fos complexes. Conversion to tumorigenicity was also paralleled by the loss of TNF-a sensitivity on viral transcription and chemokine expression (Rollins et al., 1989) , shown to correlate with a non-malignant phenotype (RoÈ sl et al., 1994 . These results suggest that AP-1 is representing an essential key element in a signal transduction pathway (zur Hausen, 1986 negatively regulating HPV E6/E7 gene expression during the multi-step process to cervical cancer.
Results
The eect of TNF-a on HPV 18 transcription in non-tumorigenic hybrid cells
Although highly tumorigenic HPV 18-positive HeLa cells, non-tumorigenic HeLa-®broblast hybrids (designated as`444') as well as tumorigenic segregants derived therefrom (further designated as`CGL3') share almost similar in vitro growth properties (Stanbridge, 1984) , the cells dier in their sensitivity against particular cytokines such as the tumor necrosis factor a (TNF-a). While HeLa-and`CGL3' cells were refractory even after overnight treatment (RoÈ sl et al., 1994) , viral transcription becomes signi®cantly downregulated in`444'-cells already 4 h after TNF-a addition (Figure 1 ). The eect on HPV 18 gene expression was selective, since other reference genes such as b-actin were not aected. Even the c-myc speci®c mRNA, which is characterized by its extremely short half-life of approximately 20 min (Dani et al., 1984) , was not in¯uenced under the same experimental conditions. Transcription of the monocyte-chemoattractant protein-1 (MCP-1) gene (Rollins et al., 1989 , Rollins, 1991 , a chemokine, which is only induced by macrophage-derived cytokines in nontumorigenic HPV-positive cells (RoÈ sl et al., 1994 (RoÈ sl et al., , 1998 , was used as a positive control to assess the biological function of TNF-a.
Dierential expression of c-Jun, c-Fos and Fra-1 in tumorigenic and non-tumorigenic HPV 18-positive cells ± Western blot analyses after TNF-a application Previous results have shown that down-regulation of viral transcription could be correlated with an altered AP-1 composition when immortalized HPV 16-positive human keratinocytes were incubated with the antioxidant pyrrolidinedithio-carbamate (PDTC). Suppression was preceded by induction and phosphorylation of c-Jun and a preferential heterodimerization with Fra-1 instead of c-Fos, whose expression became also elevated. In order to examine the regulation of these particular AP-1 components in our experimental model system, Western blot analyses were performed (Figure 2 ). The examination of`444'-cells after TNF-a application revealed a strong induction of c-Jun, an eect, which was not seen in HeLa cells. Estimating the quantity of c-Jun in`CGL3' cells, speci®c signals could be only detected after long-term`ECL' (enhanced chemiluminescence) exposure (see Figure 2) or by using more sensitive methods such as electrophoreticmobility-shift assays (EMSAs, see Figure 3A ). Furthermore, following the same kinetics, c-Jun also became phosphorylated at the serine residue at position 63, probably by activating a c-Jun Nterminal kinase (JNK) upon cytokine treatment (Sluss et al., 1994) . The absence of a TNF-a eect on c-Jun in HeLa and`CGL3'-cells can not be attributed to the lack of functional TNF-a receptors (Loetscher et al., 1991) or due to a disruption of the TNF-a signal transduction pathway (Shepard and Lewis, 1988) , since TNF-a addition triggered rapid proteolysis of the cytoplasmic inhibitory protein IkBa (Finzer et al., 1999, submitted) , which is a known hallmark for functional cytokine-mediated NF-kB activation (Traenckner et al., 1994) .
Similar to the situation as with the antioxidant (RoÈ sl et al., 1997), TNF-a-mediated reduction of HPV 18 speci®c E6/E7 transcription could be only detected in a cellular environment (`444'-cells) , where fra-1 became selectively induced. On the other hand, HeLa cells expressed low level of fra-1, which was not further elevated, while`CGL3'-cells even lacked detectable Fra-1 protein, at least under these experimental conditions (compare Figures 2 and 3) . In contrast to PDTC (RoÈ sl et al., 1997), TNF-a had only a marginal eect on c-Fos in non-tumorigenic hybrids, which was already barely expressed prior to TNF-a addition. Instead, consistent with previous results, where the quantity of c-Fos was correlated with the in vivo phenotype (O'Hara et al., 1987) , tumorigenic lines expressed considerable amounts of c-Fos, with higher levels in`CGL3'-than in parental HeLa cells. This was not a peculiarity of HPV 18-positive cells or malignant somatic cell hybrids derived therefrom, since Western blot analyses with extracts obtained from the HPV 16-positive cervical carcinoma cell SiHa also lacked Fra-1, whereas c-fos was highly expressed (Soto, Lengert and RoÈ sl, unpublished observation). Note that the`up- 5`4 44-cells' were treated with 250 units/ml of TNF-a. After 4 h, total RNA was extracted and examined by Northern blot analysis. The ®lter was consecutively hybridized with unit-length HPV 18 (`HPV 18'), the third exon of the human c-myc (`c-myc') and cDNAs encoding either the monocytechemoattractant-protein-1 (`MCP-1') or the human b-actin gene (`b-actin'). The positions of the 28S and 18S ribosomal RNA (`rRNA') in the ethidium bromide stained agarose gel are indicated Figure 2 Dierential expression of c-Jun, c-Fos and Fra-1 in somatic cell hybrids and parental HeLa cells. Non-tumorigenic HeLa-®broblast hybrids (`444'), their tumorigenic segregants (designated as`CGL3') and HeLa cells were treated with 250 unit/ml of TNF-a for 30 min (`30 min') and 4 h (`4 h'). Separation of 15 mg protein was done in two identical 12% SDS ± PAGE minigels. After electrotransfer, the ®lters were consecutively incubated either with antibodies allowing the detection of total cellular c-Jun, the phosphorylated form of c-Jun at the serine residue on position 63 (`phospho-jun') and Fra-1 or with antibodies raised against c-Fos and the upstream stimulatory factor protein USF-1 (`USF-1'). Note that for the detection of cJun in`CGL3', the lower ®lter was approximately 10-fold longer exposed (1.5 h) than the upper one. To con®rm equal protein loading, the ®lters were reincubated with a monoclonal b-actin antibody (`b-actin'). (7): untreated cells stream stimulatory factor' (`USF-1'), which can negatively interfere with AP-1 activity by interacting with Fra-1 during co-transfection experiments in murine F9 cells (Pognonec et al., 1997) cannot account for the TNF-a eect on viral gene expression in our system, since USF-1 was only marginally increased iǹ 444' cells and was even higher expressed in HeLa-and CGL3' cells. The ®lters were routinously re-incubated with a monoclonal b-actin speci®c antibody con®rming the loading and the transfer of equivalent amounts of proteins.
Electrophoretic-mobility-shift and`supershift' assays of the transcription factor AP-1 in malignant and non-tumorigenic HPV 18-positive cells
In order to examine the AP-1 composition pattern within the three dierent HPV18-positive cell lines in greater detail, EMSAs together with speci®c antibodies raised against the Jun/Fos-family members were carried out ( Figure 3A ). HPV 18 harbors two functional AP-1 binding sites within its URR (Garcia-Carranca et al., 1988) , both equally contributing to the ®nal transcription level initiated at the P 105 promoter (Thierry et al., 1992) . For EMSA analyses, we selected the distal AP-1 element at nucleotide position 7596 ± 7620 (5'-CGCACCTGGTATTAGT-CATTTTCC-3', Butz and Hoppe-Seyler, 1993) , since it is located within the constitutive enhancer region, conferring not only tissue speci®city (Oord and Beard, 1990) but also inducibility to phorbol esters (Gius and Laimins, 1989) , known to potentiate the eects of carcinogens and AP-1 activity (Arts et al., 1997) . Control experiments using a AP-1 consensus sequence (5'-CGC TT GATGACTCAG CCG GA A -3', Lee et al., 1987) in comparison with the distal HPV 18-speci®c AP-1 binding site provided identical results, indicating that there are no dierences in DNA anity and selectivity of the binding reaction (Ryseck and Bravo, 1991) . In accordance with the Western blot data (Figure 2 ), the extent of the`super-shift' revealed that both the phosphorylated and the unphosphorylated form of c-Jun represented the major dimerization partner of the Jun-family within the`444'-extracts, Figure 3 Determination of AP-1 composition by electrophoretic-mobility-shift assays (EMSA) in untreated and TNF-a treated cells. (A) AP-1 speci®c oligonucleotides were 32 P-labeled and incubated with extracts from`444'-,`CGL3'-, and HeLa cells either in the absence (7) or in the presence of speci®c antibodies raised against dierent members of the Jun/Fos-family (`c-Jun; JunB, JunD, c-Fos, Fra-1, Fra-2, FosB'). (B)`Supershift' EMSAs after TNF-a treatment (500 units/ml for 30 min, 4 and 8 h) and after Fra-1 or c-Fos antibody addition. (7): untreated control cells. The arrowheads mark the positions of AP-1 and the additionally retarded supershift' complexes followed by JunD and with substantially lower concentration by JunB ( Figure 3A ). However, regarding the situation in tumorigenic cells, there was less cJun, but more JunB (HeLa,`CGL3'). Even in extracts from tumorigenic segregants (`CGL3'), which synthesize only very low levels of c-Jun (Figure 2 , see longterm ECL exposure), a`super-shift' could be discerned.
On the other hand, the constellation was markedly dierent after dissecting individual members of the Fos-family within the respective AP-1 complexes. Most of the signal in`444' (approximately 50%, as determined after quanti®cation with a`PhosphoImager') was retarded by a Fra-1 speci®c antibody, strongly indicating that Fra-1 is the major dimerization partner of c-Jun and JunD. This was in marked contrast to HeLa and`CGL3'-cells, where Fra-1 was present in much lower concentrations with values ranging from 6 to 15% of the retarded input activity. Conversely, Fra-2, which was barely seen in`444'-cells, is expressed both in`CGL3'-and HeLa cells. c-Fos was readily detectable in`CGL3' extracts and to a lesser extent in HeLa, whereas`444'-cells completely lacked c-fos expression even after long-term exposure of the autoradiographs for more than 3 days (not shown). Finally, FosB was completely absent in all cell lines.
By examining AP-1 composition with Fra-1 and cFos reactive antibodies in`super-shift' EMSAs after TNF-a addition ( Figure 3B ), c-fos, as a immediate early response gene (Angel and Karin, 1991) , became clearly induced after 30 min in`CGL3' cells and declined back to baseline level of the untreated control after 8 h ( Figure 3B , middle). A similar picture, but to a lesser extent, emerged in HeLa cells, where c-Fos was weakly detectable under these exposition conditions. Despite c-Fos was also marginally induced in`444'-cells (Figure 2 ), the protein was not detectable in`444'-speci®c AP-1 complexes, although the corresponding cfos mRNA was expressed at roughly the same extent as found in HeLa-and CGL3 cells (data not shown).
As also depicted in Figure 3B , the amount of Fra-1 within the`444' speci®c AP-1 complex was evidently saturated, since there was no further increase after TNF-a application, although the protein was found to be induced when the same nuclear extracts were monitored in Western blot analysis (compare Figures  2 and 3B ). In contrast, cytokine treatment was not further augmenting Fra-1 in HeLa-or`CGL3' extracts, since roughly the same ratio was maintained ( Figure  3a) . Performing a binding reaction with the octamer binding factor Oct-1 (Scheidereit et al., 1988) , a transcription factor, known to negatively interfere with HPV18 URR-directed transcription at least in transient transfection assays (Hoppe-Seyler et al., 1991) , no signi®cant quantitative changes betweeǹ 444'-and HeLa cells have been visualized (not shown). These data indicate that alterations in AP-1 composition were speci®c and do not represent the result of a general variation in the expression pro®le of particular transcription factors in somatic cell hybrids in comparison with non-fused cervical carcinoma cells.
Transfection of non-malignant`444'-cells with a c-fos expression vector
In a further step we determined whether the absence of c-Fos in favor of Fra-1 might be causally involved in the dierent cytokine sensitivity and in vivo growth of 444-cells' in immunocompromised animals. To prove this hypothesis, an expression vector encoding a cDNA for the c-fos gene ( Figure 4A ) was stably introduced iǹ 444'-cells and dierent G418 resistant clones harboring an intact transcription cassette were selected. Clones which did not contain an intact exogenous c-fos gene were also used as negative controls ( Figure 4B ). Note that all transfected clones contain the same copy number of the exogenous gene (approximately 1 ± 2 copies/cell). Figure 4C depicts a Western blot of dierent c-Fos clones in comparison with a transfected negative control, the untransfected non-tumorigenic hybrids (`444') and their tumorigenic counterparts (`CGL3'). A higher resolution SDS ± PAGE gel was applied, allowing the detection of dierent phosphorylation intermediates of c-Fos (Okazaki and , migrating as distinct bands with altered molecular weight (indicated by a bracket). Although the steady state level of the c-fos mRNA (data not shown) directly correlates with the DNA copy number ( Figure 4B ), individual clones express dierent quantities of protein, strongly indicating that posttranslational modi®cation processes control both the half-life and the amount of the ectopically expressed cFos protein. Again, re-incubation of the same ®lter with a b-actin speci®c antibody con®rmed equal protein loading. Although it has been reported that constitutive over-expression of c-fos increases the sensitivity of cells to undergo apoptosis (Mils et al., 1997) , no apparent correlation between the c-Fos levels and the appearance of apoptotic ®gures such as membrane blebbing or perinuclear chromatin condensation (Cohen, 1993) have been noted ( Figure 5 ). The phase-contrast microscopy depicts the cell morphology of three dierent clones (further designated as`clone 1, 2 and 5') in comparison with non-transfected`444'-cells, their tumorigenic segregants (`CGL3') and the parental HeLa cells. The only dierence which became evident is that c-Fos reconstitution to threshold levels induced an altered cell morphology (see`clone 1' at passage 23), which was characterized by a round, cobblestone-like cell shape with high mitotic activity. Morphology was more reminicent to the epitheloid structure of`CGL3'-cells, while`clone 2 and 5' still have a¯at, translucent and ®broblastoid cell shape similar to non-tumorigenic HeLa-®broblast hybrids (`444').
In vivo growth of c-fos reconstituted`444'-cells
In order to test whether the transfected clones dier in their in vivo growth properties, 10 7 cells of ®ve independently selected clones (`clone 1-5', see Figure  4C ) were subcutaneously inoculated each into both anks of four 6-week-old athymic nu/nu mice. HeLaas well as`CGL3' cells formed rapidly growing tumors within 2 and 3 weeks, reaching an average volume of about 1.0 ± 1.5 cm 3 (Kleine et al., 1995) . To eliminate the possibility that tumor formation was due to spontaneous segregation or clonal variation during the selection process in G418 growth medium, not only non-transfected but also transfected`444'-cells containing a disrupted c-fos transcription cassette (`clone 5') were used as additional controls. Neither these cells nor clones expressing very low amounts of c-fos (`clone 3 and 4') induced tumors after an observation period of 6 months. The initial appearance of nodules in two mice derived from`clone 2' was only temporary, which completely regressed after two additional weeks. Onlỳ clone 1', obviously expressing sucient high levels of c-Fos, formed large progressive tumors in four out of four mice on both inoculation sites. Although there was a lag period of about 20 days, cells started growing vigorously within the next weeks (Figure 6 ). Direct examination of tumor material obtained from both anks of two tumor-bearing mice for the expression of the transfected gene con®rmed that c-Fos was still expressed at high levels (approximately the twofold amount as found in CGL3 extracts, data not shown) and was not eliminated or perturbed during the inoculation time of 45 days ( Figure 7A) . By investigating the same specimen with a Fra-1 speci®c antibody, no speci®c signals migrating at the expected molecular weight position were discerned, even after ). The corresponding polyadenylation signal is provided by the Moloney-Sarcoma-Virus (`MSV') long terminal repeat (`LTR') (`MSV-LTR').`pMSc-fos' also contains a dominant selection marker (`Kan./G418') driven by the Herpes simplex virus (HSV) thymidine kinase promoter (`TK') which allows cellular growth in medium containing G418. Transcription is terminated by a HSV TK polyadenylation signal (`TK-polyA'). The plasmid`pUC19' represents the prokaryotic backbone of the pMSc-fos expression vector. (B) Southern blot analyses and restriction enzyme digestion of DNA obtained from various G418 resistant cells. Pvu II (see A) serves as an enzyme to screen for the presence of an intact c-fos transcription cassette (indicated by exclamation marks). The lane on the very left side shows 444 DNA, which was reconstituted (`recon.') by 100 ng of the puri®ed Pvu II-Pvu II c-fos fragment. The position of the endogenous and exogenous fos gene is also indicated. (C) Western blot analysis of dierent c-Fos expression levels in transfected`444-cells' (clone 1 ± 5) in comparison with untransfected`444'-,`HeLa'-, and CGL3'-cells. 25 mg protein were separated in a high-resolution 12% SDS ± PAGE gel and the ®lter was probed with a c-Fos speci®c antibody (for details, see Figure 2 ). Equal loading was con®rmed by reincubating the same ®lter with a b-actin antibody. *Marks the unspeci®c signal, the bracket indicates the dierent phosphorylation intermediates of c-Fos Figure 5 Cell morphology of transfected`444'-clones in comparison with the parental tumorigenic and non-tumorigenic somatic cell hybrids.`Clone 1, 2 and 5' represent cells expressing dierent amounts of exogeneously added c-fos (see Figure 4) . Phase-contrast microscopy. Magni®cation: 1506 loading a twofold higher amount of protein (as con®rmed by re-incubation of the same ®lter with a b-actin control antibody) ( Figure 7B ). This suggests that at least with the limits of detection by Western blot analysis (see below), tumor formation was accompanied by a counterselection against Fra-1 expression, resulting in a strong reduction of the respective protein in comparison with the initial protein level in non-transfected`444'-cells.
Composition of AP-1 in tumorigenic cells after c-fos overexpression
In order to analyse the heterodimerization pattern of AP-1 within these tumorigenic cells, tumors grown in two independent animals were separately explanted and adapted for tissue culture conditions. A comparison of the band-shift pattern of these cells as well as from late passages cells from the same clone grown in parallel under tissue culture conditions (data not shown) with the EMSA pro®le of two other non-tumorigenic transfectants (`clone 2 and 5') revealed that the Fra-1/ Jun-family ratio was drastically reduced and became similar to`CGL3' or HeLa cells (see Figure 3) . Quanti®cation by the`Phospho-Imager' showed that only between 6 and 18% of the radioactive input was retarded after Fra-1 antibody addition, respectively (Figure 8, lower right and left panel) . In contrast, clones 2 and 5, which were found to be non-tumorigenic in nude mice after an observation period of more than 6 months, still maintained the same 1 : 1 Fra-1/Jun ratio (as determined by an approximately 50% retardation of the input radioactivity after application of a Fra-1 antibody) (Figure 8 Plabeled and incubated with extracts from non-tumorigenic transfectants (clone 5 and clone 2) or with extracts of recultivated tumorigenic transfectants obtained from two dierent mice (the right¯ank tumor from mouse 1 and 2) either in the absence (7) or in the presence of speci®c antibodies raised against dierent members of the Jun/Fos-family (see Figure 3) . The arrowheads mark the positions of AP-1 and the additionally retarded`supershift' complexes Jun, JunB, JunD as well as Fra-2 or FosB were not signi®cantly modi®ed during the selection procedure, mostly conserving the pattern of`444' control cells (see Figure 3A , for comparison). By inspecting JunB, JunD and Fra-2 within the AP-1 complex of the recultivated clones, the EMSA pro®le closely resembled that of CGL3' cells, with the only exception that more c-Jun (60 and 73%) was present in the`super-shift' complex. These data indicate that the c-Fos-mediated tumorigenic conversion of non-tumorigenic HeLa-®broblast hybrids was directly paralleled by alteration in the AP-1 composition.
Tumorigenic transfectants have lost their sensitivity against TNF-a
The modi®cation of the initial AP-1 composition pattern towards the AP-1 pro®le of`CGL3' and HeLa raised the question, whether the cells obtained from explanted tumors were still responsive to cytokines. For this purpose, HPV 18 E6/E7 expression was monitored in Northern blots after addition of TNF-a at a concentration of 500 units/ml for dierent periods of time (Figure 9 ). Similar to HeLa-or`CGL3' cells, none of the recultivated clones showed an eect of TNF-a on viral gene expression, which contrasts the ®nding previously demonstrated for parental`444'-cells (see also Figure 1 ).
Since non-tumorigenic hybrids, their tumorigenic segregants and HeLa cells share comparable growth properties in tissue culture (Stanbridge, 1984) , it was proposed that viral suppression in non-malignant cells upon inoculation in nude mice (Bosch et al., 1990 ) is mediated by the attraction of cytokine-releasing macrophages, which became activated by the expression of chemokines such as the`monocyte-chemoattractant-protein-1' gene (MCP-1) (Rollins et al., 1989) . As previously shown for`CGL3'-and HeLa cells (RoÈ sl et al., 1994, see also Figure 9 ), concomitant with the inability to down-regulate HPV 18 transcription, TNF-a was also not further able to induce MCP-1 expression in the tumorigenic c-fos converted clones (Figure 9 ). This is in good agreement with our earlier data (RoÈ sl et al., 1994) , suggesting that dys-regulation of MCP-1 transcription regularly correlates with a tumorigenic phenotype (for review, see RoÈ sl et al., 1999) .
Discussion
The transcription factor AP-1 plays a crucial role in cell proliferation, dierentiation and neoplastic transformation (reviewed in Angel and Karin, 1991) . The importance of AP-1 as a positive regulator for HPV transcription has been documented in a number of studies (for review, see RoÈ sl and Schwarz, 1997) . AP-1 represents not only a central key element in the overall composition of the transcriptional machinery at the virus-speci®c upstream-regulatory region (URR), but is also a direct target for the E7 oncogene, which posttranslationally interacts with c-Jun in elevating its trans-activating activity (Antinore et al., 1996) .
Although AP-1 is considered as a transcription factor indispensible for viral gene expression, our previous results pointed already to the possibility that AP-1 might be also involved in negative regulation of HPV transcription. Changing the intracellular redox status after application of antioxidative drugs, such as pyrrolidine-dithiocarbamate (PDTC), HPV 16 speci®c E6/E7 gene expression was selectively suppressed at the level of initiation of transcription, which is accompanied by modi®cations in AP-1 composition. These alterations of the AP-1 transcription complex were characterized by an enhanced c-Jun/JunB association with Fra-1, while c-Fos, the canonical dimerization partner remained largely excluded (RoÈ sl et al., 1997). The potential involvement of fra-1 in the context of HPV negative regulation could be of functional relevance, since this gene is located on chromosome 11 (Sinke et al., 1993) , known to have tumor suppressing function after micro-cell transfer either into HPV 16 (SiHa) or into HPV 18 positive cervical carcinoma cell lines (HeLa) (Saxon et al., 1986; Koi et al., 1989) . A further aspect which may support this notion is the chromosomal localization of fra-1 within a region (11q13) (Sinke et al., 1993) , often found to be structurally deleted or rearranged in certain cervical carcinoma cells (Jesudasan et al., 1995) .
Assuming that AP-1 either acts directly or indirectly as a point of integration of distinct signaling pathways diering in malignant and non-malignant cells, we used HPV 18-positive cervical carcinoma cell line HeLa, non-tumorigenic HeLa-®broblast hybrids (designated as`444') and tumorigenic segregants derived therefrom (designated as`CGL3') (Stanbridge, 1984) to study HPV18 gene expression in a genetically de®ned cell system (Srivatsan et al., 1991) . Dierences in the transcriptional regulation of the very same HPV 18 transcription cassette embedded in cells diering only in their chromosomal complement (RoÈ sl et al., 1988) became not only evident by the transcriptional suppression of HPV 18 E6/E7 mRNA exclusively in non-tumorigenic hybrids after heterotransplantation into immunocompromised animals (Bosch et al., 1990) , but also by their diering sensitivity against macrophage-derived cytokines (RoÈ sl et al., 1994; Kleine et al., 1995; see also Figures 1 and 9 , respectively). To investigate whether these dierences can be correlated either with already pre-existing or TNF-a induced alterations in AP-1 composition, Western blots and electrophoretic-mobility shift assays (EMSA) were performed (see Figures 2 and 3 ). In accordance with previous observations (RoÈ sl et al., 1997), virus-speci®c down-regulation again occurred only in a cellular environment (`444'-cells) , where the AP-1 complexes were characterized by a predominant prevalence of Fra-1 in comparison to c-Fos. Calculating the ratio of Fra-1 after addition of speci®c antibodies, almost 50% of the input radioactivity was retarded, indicating that Fra-1 was the major dimerization partner of c-Jun, JunB and JunD in`444'-extracts ( Figure 3A) . TNF-a addition further elevated Fra-1 concentration (Figure  2) , an eect, which was not detectable in the corresponding tumorigenic lines. HeLa cells expressed a low and TNF-a non-inducible quantity of fra-1, while in tumorigenic segregants, Fra-1 was only barely visible in EMSAs (Figure 3 ), but not in Western blot analysis (Figure 2 ). Direct quantitation of`CGL3' and HeLa speci®c AP-1 complexes revealed that Fra-1 is represented only in a proportion, ranging from 6 ± 15%, respectively of the input radioactivity.
Despite of the fact that enhanced fra-1 expression can abolish the trans-activation of c-Jun/c-Fos complexes on AP-1 responsive marker genes (Suzuki et al., 1991; Yoshioka et al., 1995) , the simple over-expression of fra-1 failed to signi®cantly suppress HPV 16/18 URR-controlled reporter constructs in transient cotransfection assays (not shown). This ®nding either re¯ects a balanced stoichiometry of combinatorial acting transcription factors or the requirement of post-translational modi®cation events (e.g. phosphorylation) of the respective AP-1 components (Hunter and Karin, 1992) , both eects, which cannot be mimicked under transient transfection conditions. Alternatively, it is also conceivable that additional, still unknown upstream or downstream signaling cascades or accessory proteins are required to negatively interfere with HPV transcription, which become only activated after cytokine treatment (see below). Stable introduction of`antisense' constructs directed against fra-1 in 444 cells should answer the question, whether the neutralization of fra-1 under physiological conditions could induce tumorigenicity in nude mice.
Conversely, considering the expression of c-fos, a quite dierent picture emerged. Evidence has been provided that c-fos is one of those candidate genes being consistently found to be elevated after segregation of formerly non-tumorigenic hybrids to a tumorigenic phenotype (O'Hara et al., 1987) . In agreement with this study, our malignant cells (`CGL3' and HeLa) also expressed signi®cant high amounts of the c-Fos protein (Figures 2 and 3) . In contrast, as evidenced by`super-shift'-EMSAs after addition of c-Fos speci®c antibodies, the same protein is not detectable within the AP-1 transcription complexes derived from non-tumorigenic hybrids ( Figure 3A) . Although the viral oncoproteins E6/E7 possess a trans-stimulatory activity on the c-fos promoter (Morosov et al., 1994) , this eect cannot account for the divergent c-fos regulation in our experimental system, because all three cell lines harbor similar levels of the virus-speci®c mRNAs (Figure 8 ), directly correlating with the amount of the corresponding proteins.
On the other hand, it has been shown that the halflife of c-Fos depends on the phosphorylation status of c-Jun at its N-terminal trans-activation domain (Papavassiliou et al., 1992; Tsurumi et al., 1995) . The application of a phosphorylation speci®c c-Jun antibody (directed against the serine residue at position 63) revealed that detectable c-Jun phosphorylation can only be discerned after TNF-a addition (Figure 2) . Since c-Fos, however, is already weakly expressed in the non-treated cells (Figure 2) , it seems unlikely at the ®rst sight that c-Jun is controlling the half-life of c-Fos via this particular pathway. However, it cannot be completely ruled out at the moment that c-Jun is already phosphorylated at other acceptor sites, which targets c-Fos for degradation catalysed by the 26S proteasome complex (Tsurumi et al., 1995) , since the corresponding mRNA is found to be expressed in`444' cells (data not shown). This aspect will be analysed in subsequent studies. The reason why c-Jun was not induced and phosphorylated in HeLa cells, despite the presence of functional and through UV irradiation, inducible Jun-N-terminal-kinases (JNKs) , is presently not clear and remains to be elucidated.
Assuming that a pre-existing AP-1 composition between c-Jun/JunB/JunD and Fra-1 found in`444'-cells (Figure 3 ) is an essential prerequisite and component of a signaling pathway negatively regulating HPV transcription in non-tumorigenic cells, one may predict that the reconstitution of the AP-1 complex in favor to c-Fos should alter both the cytokine responsibility and the in vivo growth properties of formerly non-malignant cells. As demonstrated above, ectopic overexpression of c-fos (Figure 4 ) indeed led to the appearance of tumorigenic cells (Figure 6 ), in which the AP-1 composition was changed towards the constellation found in tumorigenic`CGL3'-and HeLa cells (Figure 8) .
It has been reported that at least in rodent cells, fra-1 is positively controlled by c-Jun and c-Fos through regulatory sequences within its ®rst intron, which comprise several AP-1 binding sites (Bergers et al., 1995) . Although a similar homology is also found at the 5'-end of the human fra-1 gene (Tsuchiya et al., 1993) , the absence of detectable Fra-1 protein within arising tumors ( Figure 7B ), as well as its continuous reduction within the AP-1 transcription complexes of recultivated tumor cells (Figure 8 ) argues against such a mechanism in human cells. It seems that the reduction of Fra-1 in favor of ectopically expressed cFos protein represents a speci®c time-dependent selection process, which might be of general importance in the multi-step concept of HPV-linked carcinogenesis. Our recent data, demonstrating that three out of six established cervical carcinoma cell lines either failed to reveal detectable Fra-1 or express the protein in low, but non-inducible amounts (not shown), also point in this direction. Furthermore, it should be stressed that the described c-fos/fra-1 regulation is not a peculiarity of our hybrid system, since transfections of v-fos also induces tumorigenicity in HPV 18-immortalized human keratinocytes (Pei et al., 1993) . Although this study did not followed up the fate of v-fos in molecular terms, it emphasizes the signi®cant role of AP-1 in HPV-mediated cell transformation.
Hence, alterations in AP-1 composition may represent an elegant way to regulate the same gene in a diverse fashion (Wang et al., 1996) . Considering the mouse skin for example, AP-1 family members are tightly regulated in the course of cell dierentiation (Rutberg et al., 1996) . Reminicent of our study, dierentiation inducing agents such as calcium repressed transcription of certain marker genes by excluding c-fos in favor to fra-1 and fra-2, while 12-Otetradecanoylphorbol-13-acetat (TPA) is exerting just the opposite eect (Rutberg et al., 1997) .
The observation that overexpression of c-fos rendered HPV 18 transcription refractory to TNF-a (Figure 9 ) may provide a causal link between cytokine sensitivity and AP-1 composition in HPV negative regulation. Moreover, as previously shown, viral gene expression becomes selectively suppressed when nonmalignant cells were injected in nude mice (Bosch et al., 1990) . It is assumed that transcriptional downregulation is mainly mediated by macrophages and macrophage-derived cytokines . It is intriguing that TNF-a also failed to induce the expression of the monocyte-chemoattractant protein-1 (Rollins et al., 1989; Rollins, 1991) , a factor, to mediate the recruitment and chemotactic attraction of activated macrophages .
In conclusion, our present data suggest that AP-1 composition plays not only an important role as a positive regulator for HPV transcription, but must be also considered as a central control element within a hierarchy of an intracellular surveillance mechanism negatively regulating HPV-directed E6/E7 expression in non-malignant towards tumorigenic cells.
Materials and methods

Cell lines and cytokine treatment
HPV 18-positive cervical carcinoma cells (HeLa), nontumorigenic somatic cell hybrids made between HeLa cells and normal human ®broblasts (`444-cells') and the corresponding tumorigenic segregants (`CGL3') (Stanbridge, 1984) were maintained in Dulbecco's modi®ed Eagle's medium, supplemented with 10% fetal calf serum, 1% penicillin/ streptomycin. For cytokine treatment, the cells were incubated with TNF-a (speci®c activity: 1610 8 units/mg) (Pharma Biotechnologie, Hannover, Germany) for dierent periods of time as described in the ®gure legends.
Transfections and DNA analysis
To establish c-fos expressing clones of HPV 18 positive, nontumorigenic HeLa-®broblast hybrids (`444-cells'), 1610 6 cells were transfected with an expression plasmid (`pMSc-fos') harboring the c-fos gene under the control of the SV40 enhancer/promoter element and dominant selection marker conferring G418 (Geneticin) resistance (kindly provided by Rolf MuÈ ller, UniversitaÈ t Marburg, Germany) using the Lipofectamine precipitation procedure (Gibco, BRL). After re-plating, the cells were challenged for growth in the presence of 1.5 mg/ml G418 (Gibco, BRL). Approximately 2 ± 3 weeks later, G418 resistant clones were picked and expanded. Total cellular DNA was extracted using standard procedures (Sambrook et al., 1989) . The puri®ed DNA was digested with appropriate restriction enzymes to select for G418 resistant clones harboring an intact transcription cassette of the exogenous c-fos gene. The DNAs were electrophoresed in 1% agarose gels, transferred to Gene Screen Plus membranes (DuPont, NEN) and the ®lters were hybridized with the corresponding insert for 1 day at 428C in the presence of 50% formamide. Washing was done in 26SSC, 0.1% SDS at 688C.
RNA analysis
RNA was extracted according to the guanidinium-thiocyanate method (Chomczynski and Sacchi, 1987) . Approximately 5 mg of total cellular RNA was separated on 1% agarose gels in the presence of ethidium bromide under non-denaturating conditions (Khandjian and Meric, 1986 ) and transferred to GeneScreen Plus membranes (DuPont, NEN). The ®lters were subsequently hybridized with speci®c probes, which were labeled with 32 P-dCTP by the random priming method (Feinberg and Vogelstein, 1984) .
DNA hybridization probes
pHPV 18 represent unit-length of HPV 18 (Boshart et al., 1984) cloned in pBR322. pHFA1 (Gunning et al., 1983) , harboring an approximately full-length insert of the ®broblast b-actin gene was a generous gift from L Kedes (Medical Center, Palo Alto, USA). The full length cDNA encoding the monocyte-chemoattractant-protein-1 (MCP-1) (Rollins et al., 1989) , cloned as a 0.74 kb KpnI fragment in a pGEM vector (Promega) was obtained from the American Type Culture Collection (Rockville, MD, USA). The plasmid pc-myc containing the third exon of the human c-myc gene was kindly made available by G Bornkamm (Institut fuÈ r Klinische Molekularbiologie, MuÈ nchen, Germany) (Polack et al., 1987) . The DNA harboring the human homologue for the Fra-1 gene (Fuiji et al., 1991) was a generous gift from M Seiki (Cancer Research Institute, Kanagawa, Japan).
Electrophoretic mobility shift assays
For gel-retardation tests the following oligonucleotides were used: a AP-1 consensus sequence 5'-CGCTTGATGACT-CAGCCGGAA-3' (Lee et al., 1987) , a HPV 18 speci®c AP-1 binding site 5'-CGCACCTGGTATTAGTCATTTTCC-3', position 7596 ± 7620 (Butz and Hoppe-Seyler, 1993 ) and the Oct-1 consensus oligonucleotide: 5'-TGTCGAATGCAAAT-CACTAGAA-3' (Scheidereit et al., 1988) . The DNAs were synthesized in an Applied Biosystems synthesizer using a phosphoramitide chemistry and further puri®ed by HPLC. For electrophoretic mobility shift assays, the annealed oligonucleotides were labeled with 32 P-g-ATP (Amersham, 3000 Ci/mmol) with T4 polynucleotide kinase and gelpuri®ed from a 15% polyacrylamid gel.
Cellular extracts were prepared as described (Schreiber et al., 1989) with the only modi®cation that that N-N-(L-3-trans-carboxyoxirane-2-carbonyl)-L-leucyl-agmatine (E64) and 4-(2-Aminoethyl)-benzolsulfonyl¯ourid (`Pefabloc SC') were included as protease inhibitors in concentrations suggested by the manufacturer (Boehringer, Mannheim, Germany). Protein concentration was determined by the Bradford method (Biorad) using de®ned amounts of BSA as standard. The binding was performed in a 25 ml reaction volume containing 10% glycerol, 12 mM HEPES pH 7.9, 4 mM Tris-HCL pH 7.9, 60 mM KCL, 1 mM EDTA, 1 mM DTT, 20 mg/ml BSA, 2.5 mg poly(dI-dC) and 2 mg nuclear extract. After 5 min, 10 000 c.p.m. of the 32 P-g-ATP 5'-end labeled double-stranded oligonucleotide probe was added and the incubation was continued for additional 30 min at room temperature. The sequence speci®city of the binding was routinely determined in competition experiments by the addition of a 100-fold molar excess of either unlabeled homologous or heterologous oligonucleotides (RoÈ sl et al., 1997).
AP-1 composition in malignant and non-malignant HPV-positive cells U Soto et al
For monitoring AP-1 composition in supershift-assays, 2 mg of polyclonal antibodies directed against the Jun/Fos family were added and the reaction was further incubated for 1 h at 48C. In detail, the following antibodies (Ab) (all obtained from Santa Cruz, Biotechnology as`TransCRuz 2 ' supershift reagents) were used: c-Fos-Ab (epitope corresponding to amino acids 3 ± 16 mapping at the N-terminus of human c-Fos protein); FosB-Ab: (epitope corresponding to amino acids 102 ± 117 of the mouse FosB protein). Fra-1-Ab (epitope corresponding to amino acids 3 ± 22 mapping at the N-terminus of the human Fra-1 protein); Fra-2-Ab: (epitope corresponding to amino acids 3 ± 22 mapping at the Nterminus of the human Fra-2 protein). For the jun-gene family: c-Jun-Ab, which recognizes both the unphosphorylated and phosphorylated form of c-Jun (epitope corresponding to amino acids 56 ± 69 mapping within the amino-terminal domain of the mouse c-Jun protein). JunB-Ab: (epitope corresponding to amino acids 210 ± 222 mapping within the carboxy-terminal domain of the mouse JunB protein); JunDAb: (epitope corresponding to amino acids 329 ± 341 mapping within the carboxy terminus of mouse JunD). The speci®city of the supershift reaction was determined by addition Jun/ Fos antibodies to binding reactions with oligonucleotides harboring the Oct-1 consensus sequence. The DNA-protein complexes were resolved on 4.5 and 5.5% non-denaturating polyacrylamidgel (29 : 1 cross-linking ratio), dried and exposed overnight to Kodak X-Omat ®lms. The ratio of the retarded complexes after antibody addition (`supershift' assay) was quantitated with a Molecular Dynamics Phosphoimager (Johnston et al., 1990 ) using the`Image Quant' program as software.
SDS ± PAGE and Western blotting
The same extracts (15 ± 25 mg) used for the band-shift analyses were separated in 10 ± 12% SDS-polyacrylamide gels (PAGE), electrotransferred to Immobilon-P membranes (PVDF, Millipore Corporation, Bedford, MA, USA) and probed with the following antibodies: c-Jun antibody (epitope corresponding to amino acids 1 ± 79 of the human c-Jun) recognizes total c-Jun levels in the cell (Biolabs); a c-Jun antibody (`PhosphoPlus 2 '), directed against the phosphorylation speci®c form of the c-Jun at the serine residue at position 63 (Biolabs) and a polyclonal antibody raised against the amino acids 291 ± 310 at the carboxyterminal region of thè upstream stimulatory factor' USF-1 (Santa Cruz Biotechnology). The incubation was carried out overnight in phosphatebuered saline (PBS) supplemented with 5% skim milk powder (Merck), 0.05% Tween 20 (Sigma) and a 1 : 5000 dilution of the respective antibody. The bands were visualized with an anti-rabbit IgG antibody conjugated with a horseradish peroxidase using the ECL (enhanced chemiluninescence) detection system (Amersham). Equal protein transfer and loading was routinously controlled by re-incubating the ®lters with a monoclonal b-actin speci®c antibody (ICN Biomedicals). For re-incubation with additional antibodies, the ®lters were stripped in a solution consisting of 50 mM Tris-HCL (pH 6.8), 2% SDS and 0.1 M b-mercaptoethanol for 30 min at 508C.
Tumorigenicity assays and in vitro recultivation of tumorigenic cells
1610
7 transfected`444-cells' harboring the right size insert of the c-Fos gene were trypsinised, washed twice and resuspended in 100 ± 150 ml PBS. To exclude possible tumor formation due to clonal variations during the selection in G418 growth medium, not only untransfected but also transfected`444-cells' containing a disrupted c-Fos transcription cassette were used as additional controls. The cells were subcutaneously inoculated into the right and left¯ank of 6-week-old female nude mice (nu/nu). Four mice per clone were injected, corresponding to eight inoculation sites. Tumor size was monitored twice a week using the formula V=0.46A6B 2 , where A and B are the larger and the smaller axis, respectively (Attia and Weiss, 1966) . As a positive control for tumor formation, both tumorigenic segregants (`CGL3') and parental HeLa cells were used. Transfectants were considered as non-tumorigenic when no nodule formation could be noted after an observation period of 6 months. Tumors were surgically removed and subdivided in dierent parts for histological evaluation, DNA-, RNAand protein analyses. For recultivation of tumorigenic cells, tumor specimens were cut into small pieces, treated for 30 min with trypsin and spread on the dry surface of a tissue culture plate. After 15 min, fresh medium without G418 was carefully added, which also favors the outgrowth of mouse ®broblasts, acting as a feeder to improve the recultivation eciency. After 5 ± 10 days, cells were passaged and challenged for growth in G418 containing medium to remove contaminating mouse ®broblasts.
